Superworth

DexCom price to sales ratio DXCM

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026
5.9×
10-year median
12.2×
Against its 10-year history
6th
percentile: 0 is its lowest day, 100 its highest
10-year range
4.8× to 27.0×
Peer median
3.1×

DexCom's price to sales ratio is 5.9× as of Oct 23, 2026.

That is below its ten-year median of 12.2×, lower than on 94% of days in the last ten years.

Over that time it ranged from 4.8× in Nov 2025 to 27.0× in Nov 2021.

The median for 9 medical device stocks of a similar size is 3.1×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far5.9×4.9×7.0×
20255.8×4.8×8.8×
20247.9×6.5×14.8×
202314.1×9.2×17.6×
202215.7×10.5×21.1×
202122.4×15.9×27.0×
202019.5×13.0×25.4×
201914.8×9.5×15.4×
201811.5×6.6×15.3×
20177.5×6.1×13.5×
20169.5×9.5×18.2×
201518.7×17.8×25.1×
201418.6×13.3×22.0×
201317.8×10.6×18.1×
201210.3×8.4×12.3×

Against its peers

Companies in Medical - Devices nearest DexCom's size, closest first, today.

CompanyPrice to sales ratio
DXCMDexCom5.9×
GEHCGE HealthCare Technologies1.5×
ZBHZimmer Biomet2.2×
EWEdwards Lifesciences7.9×
BSXBoston Scientific3.2×
SYKStryker4.6×
MDTMedtronic3.3×
ABTAbbott Laboratoriesn/m
LIVNLivaNova3.0×
ITGRInteger2.3×
Peer median3.1×

Where DexCom ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on DexCom

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.